Immunome, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3
Immunome, Inc. (IMNM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 of $0 for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-16.
Discontinued › Notes › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 · last filed 2020-11-16
- 2020-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 9 month $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 9 month |
|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |